cysteine hydrochloride
PreclinicalSmall molecule
cysteine hydrochloride is one of 9 small molecule programs targeting Erythropoietic Protoporphyria. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Erythropoietic Protoporphyria
#DrugCompanyPhaseTrials
1Scenesse
CClinuvel Pharmaceuticals Limited
Phase 3
Tagamet
DDT MedTech, LLC
Phase 2
MT-7117
TTanabe Pharma America, Inc.
Phase 3
Bitopertin
RochePhase 1
Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
PORT-77
PPortal Therapeutics, Inc.
Phase 2
Iron
WWatson Pharmaceuticals
Preclinical
DISC-1459
DDisc Medicine, Inc
Preclinical
cysteine hydrochloride
FFDA Office of Orphan Products Development
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Erythropoietic Protoporphyria2 trials
Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria
Completed·—·Phase 3·NCT00004940·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for cysteine hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details